vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and FREQUENCY ELECTRONICS INC (FEIM). Click either name above to swap in a different company.
FREQUENCY ELECTRONICS INC is the larger business by last-quarter revenue ($17.1M vs $15.0M, roughly 1.1× CHAMPIONS ONCOLOGY, INC.). FREQUENCY ELECTRONICS INC runs the higher net margin — 10.5% vs 1.8%, a 8.7% gap on every dollar of revenue. On growth, CHAMPIONS ONCOLOGY, INC. posted the faster year-over-year revenue change (11.5% vs 8.3%). FREQUENCY ELECTRONICS INC produced more free cash flow last quarter ($-1.1M vs $-2.0M). Over the past eight quarters, CHAMPIONS ONCOLOGY, INC.'s revenue compounded faster (11.8% CAGR vs 11.8%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
Ultra Electronics Holdings is a British defence and security company. It was listed on the London Stock Exchange and was a constituent of the FTSE 250 Index until it was acquired by Cobham, which is itself owned by Advent International.
CSBR vs FEIM — Head-to-Head
Income Statement — Q2 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $17.1M |
| Net Profit | $268.0K | $1.8M |
| Gross Margin | 51.7% | 38.2% |
| Operating Margin | 1.2% | 10.0% |
| Net Margin | 1.8% | 10.5% |
| Revenue YoY | 11.5% | 8.3% |
| Net Profit YoY | -63.2% | -32.1% |
| EPS (diluted) | $0.02 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $17.1M | ||
| Q3 25 | $14.0M | $13.8M | ||
| Q2 25 | $12.4M | $20.0M | ||
| Q1 25 | $17.0M | $18.9M | ||
| Q4 24 | $13.5M | $15.8M | ||
| Q3 24 | $14.1M | $15.1M | ||
| Q2 24 | $14.0M | $15.6M | ||
| Q1 24 | $12.0M | $13.7M |
| Q4 25 | $268.0K | $1.8M | ||
| Q3 25 | $-436.0K | $634.0K | ||
| Q2 25 | $-1.8M | $3.2M | ||
| Q1 25 | $4.5M | $15.4M | ||
| Q4 24 | $728.0K | $2.7M | ||
| Q3 24 | $1.3M | $2.4M | ||
| Q2 24 | $-109.0K | $2.6M | ||
| Q1 24 | $-2.5M | $130.0K |
| Q4 25 | 51.7% | 38.2% | ||
| Q3 25 | 42.9% | 36.8% | ||
| Q2 25 | 41.1% | 37.5% | ||
| Q1 25 | 61.2% | 43.8% | ||
| Q4 24 | 44.9% | 48.2% | ||
| Q3 24 | 49.7% | 44.4% | ||
| Q2 24 | 48.2% | 40.3% | ||
| Q1 24 | 34.7% | 22.6% |
| Q4 25 | 1.2% | 10.0% | ||
| Q3 25 | -3.8% | 2.6% | ||
| Q2 25 | -16.2% | 16.4% | ||
| Q1 25 | 26.4% | 18.3% | ||
| Q4 24 | 5.4% | 16.5% | ||
| Q3 24 | 9.5% | 15.7% | ||
| Q2 24 | -1.9% | 16.0% | ||
| Q1 24 | -21.4% | -3.4% |
| Q4 25 | 1.8% | 10.5% | ||
| Q3 25 | -3.1% | 4.6% | ||
| Q2 25 | -14.9% | 16.0% | ||
| Q1 25 | 26.4% | 81.4% | ||
| Q4 24 | 5.4% | 16.8% | ||
| Q3 24 | 9.3% | 16.1% | ||
| Q2 24 | -0.8% | 16.9% | ||
| Q1 24 | -21.1% | 0.9% |
| Q4 25 | $0.02 | $0.18 | ||
| Q3 25 | $-0.03 | $0.07 | ||
| Q2 25 | $-0.12 | $0.33 | ||
| Q1 25 | $0.31 | $1.60 | ||
| Q4 24 | $0.05 | $0.28 | ||
| Q3 24 | $0.09 | $0.25 | ||
| Q2 24 | $-0.01 | $0.28 | ||
| Q1 24 | $-0.19 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $3.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $58.5M |
| Total Assets | $30.2M | $92.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $3.0M | ||
| Q3 25 | $10.3M | $4.5M | ||
| Q2 25 | $9.8M | $4.7M | ||
| Q1 25 | $3.2M | $5.5M | ||
| Q4 24 | $2.8M | $9.7M | ||
| Q3 24 | $2.9M | $16.2M | ||
| Q2 24 | $2.6M | $18.3M | ||
| Q1 24 | $4.5M | $11.7M |
| Q4 25 | $4.2M | $58.5M | ||
| Q3 25 | $3.5M | $56.3M | ||
| Q2 25 | $3.8M | $55.6M | ||
| Q1 25 | $5.5M | $51.8M | ||
| Q4 24 | $681.0K | $36.2M | ||
| Q3 24 | $-332.0K | $33.2M | ||
| Q2 24 | $-1.9M | $39.8M | ||
| Q1 24 | $-2.1M | $36.7M |
| Q4 25 | $30.2M | $92.3M | ||
| Q3 25 | $30.5M | $93.2M | ||
| Q2 25 | $32.3M | $93.7M | ||
| Q1 25 | $30.6M | $86.4M | ||
| Q4 24 | $25.2M | $77.8M | ||
| Q3 24 | $24.9M | $84.3M | ||
| Q2 24 | $26.1M | $83.3M | ||
| Q1 24 | $26.8M | $77.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $-523.0K |
| Free Cash FlowOCF − Capex | $-2.0M | $-1.1M |
| FCF MarginFCF / Revenue | -13.1% | -6.6% |
| Capex IntensityCapex / Revenue | 1.6% | 3.6% |
| Cash ConversionOCF / Net Profit | -6.47× | -0.29× |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | $-5.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $-523.0K | ||
| Q3 25 | $600.0K | $1.2M | ||
| Q2 25 | $6.9M | $-155.0K | ||
| Q1 25 | $490.0K | $-3.6M | ||
| Q4 24 | $-283.0K | $3.8M | ||
| Q3 24 | $311.0K | $-1.5M | ||
| Q2 24 | $-1.8M | $7.5M | ||
| Q1 24 | $-919.0K | $4.2M |
| Q4 25 | $-2.0M | $-1.1M | ||
| Q3 25 | $554.0K | $385.0K | ||
| Q2 25 | $6.6M | $-786.0K | ||
| Q1 25 | $448.0K | $-4.0M | ||
| Q4 24 | $-377.0K | $3.3M | ||
| Q3 24 | — | $-1.8M | ||
| Q2 24 | $-1.8M | $6.7M | ||
| Q1 24 | $-1.0M | $3.9M |
| Q4 25 | -13.1% | -6.6% | ||
| Q3 25 | 4.0% | 2.8% | ||
| Q2 25 | 53.5% | -3.9% | ||
| Q1 25 | 2.6% | -20.9% | ||
| Q4 24 | -2.8% | 20.8% | ||
| Q3 24 | — | -11.8% | ||
| Q2 24 | -13.0% | 42.8% | ||
| Q1 24 | -8.4% | 28.4% |
| Q4 25 | 1.6% | 3.6% | ||
| Q3 25 | 0.3% | 5.6% | ||
| Q2 25 | 2.0% | 3.2% | ||
| Q1 25 | 0.2% | 1.7% | ||
| Q4 24 | 0.7% | 3.3% | ||
| Q3 24 | 0.0% | 2.2% | ||
| Q2 24 | 0.0% | 5.3% | ||
| Q1 24 | 0.8% | 2.3% |
| Q4 25 | -6.47× | -0.29× | ||
| Q3 25 | — | 1.83× | ||
| Q2 25 | — | -0.05× | ||
| Q1 25 | 0.11× | -0.24× | ||
| Q4 24 | -0.39× | 1.44× | ||
| Q3 24 | 0.24× | -0.60× | ||
| Q2 24 | — | 2.85× | ||
| Q1 24 | — | 32.36× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
FEIM
| POC Revenue | $14.8M | 86% |
| POT Revenue | $2.3M | 13% |
